Skip to main content
. 2023 Jun 12;82(9):1130–1141. doi: 10.1136/ard-2023-223916

Figure 6.

Figure 6

Exposure-adjusted incidence of serious infection. ADA, adalimumab; csDMARD, conventional synthetic disease-modifying antirheumatic drug; CV, cardiovascular; EAIR, exposure-adjusted incidence rate; EOW, every other week; MTX, methotrexate; PY, patient-years; QD, once daily; UPA, upadacitinib.